Case Reports
doi: 10.1016/j.leukres.2008.01.015.
Epub 2008 Mar 5.
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
- PMID: 18321570
- DOI: 10.1016/j.leukres.2008.01.015
Item in Clipboard
Case Reports
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
Leuk Res.
2008 Oct.
No abstract available
Similar articles
-
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.Intern Med. 2012;51(19):2763-6. doi: 10.2169/internalmedicine.51.8314. Epub 2012 Oct 1. Intern Med. 2012. PMID: 23037470
-
Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.Biomedica. 2014 Jan-Mar;34(1):48-59. doi: 10.1590/S0120-41572014000100008. Biomedica. 2014. PMID: 24968906
-
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.Value Health. 2011 Dec;14(8):1057-67. doi: 10.1016/j.jval.2011.07.006. Epub 2011 Oct 12. Value Health. 2011. PMID: 22152175
-
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47. J Hematol Oncol. 2010. PMID: 21108851 Free PMC article. Review.
-
Management of the new patient with CML in chronic phase.Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0. Curr Hematol Malig Rep. 2013. PMID: 23381448 Review.
Cited by
-
Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin.Int J Hematol. 2013 Jan;97(1):135-8. doi: 10.1007/s12185-012-1222-7. Epub 2012 Nov 23. Int J Hematol. 2013. PMID: 23179903
-
Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.Saudi J Med Med Sci. 2022 Sep-Dec;10(3):183-191. doi: 10.4103/sjmms.sjmms_492_21. Epub 2022 Sep 7. Saudi J Med Med Sci. 2022. PMID: 36247049 Free PMC article. Review.
-
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.Sci Rep. 2017 May 8;7(1):1578. doi: 10.1038/s41598-017-01822-0. Sci Rep. 2017. PMID: 28484277 Free PMC article.
-
Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation.Cell. 2011 Sep 30;147(1):173-84. doi: 10.1016/j.cell.2011.08.034. Cell. 2011. PMID: 21962514 Free PMC article.
-
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.Front Pharmacol. 2024 Feb 1;15:1355171. doi: 10.3389/fphar.2024.1355171. eCollection 2024. Front Pharmacol. 2024. PMID: 38362147 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
